İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2024 · article

CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

ISSN2473-9529
YÖKSİS OpenAlex Açık erişim · gold Üst %10
Yıl2024
Atıf18OpenAlex
Yüzdelik%96,2
FWCI5,191,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q1

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıBlood Advances
  • Katalog eşleşmesi (ISSN)Blood Advances
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

ABSTRACT: Copanlisib, a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α and δ isoforms, previously demonstrated durable responses as monotherapy and improved progression-free survival (PFS) in combination with rituximab in patients with relapsed indolent non-Hodgkin lymphoma (iNHL). CHRONOS-4 was a phase 3, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of copanlisib in combination with standard immunochemotherapy in patients with relapsed iNHL. Patients (n = 524) were randomized (1:1) to copanlisib (60 mg IV) plus immunochemotherapy (rituximab and bendamustine [R-B] or placebo plus R-B). Copanlisib/placebo were administered with R-B (days 1, 8, and 15 of each 28-day cycle) for ≤6 cycles and as monotherapy from cycle 7 up to 12 months. The primary study end point was PFS. Median exposure was 8.5 months (0.2-12.9) for copanlisib plus R-B and 11.4 months (0.1-12.6) for placebo plus R-B. Median PFS was 32.9 months (95% confidence interval [CI], 24.4-38.6) for copanlisib plus R-B and 33.3 months (95% CI, 27.8-42.8) for placebo plus R-B (hazard ratio, 1.13; 95% CI, 0.88-1.44; P = .83). No differences between treatment arms were observed in overall survival (data not yet mature), objective response rate, and duration of response for the overall population or individual histology types. Overall, copanlisib plus R-B was associated with higher rates of serious treatment-emergent adverse events (TEAEs), grade 4 and 5 TEAEs, and treatment discontinuation. A number of serious TEAEs were infections. Overall, copanlisib plus R-B did not provide clinical benefit vs placebo plus R-B and was associated with worse tolerability in patients with relapsed iNHL. This trial was registered at www.ClinicalTrials.gov as #NCT02626455.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

18atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yazarlar

26
  1. Pier Luigi Zinzani 1
  2. Huaqing Wang 2
  3. Jifeng Feng 3
  4. Tae Min Kim 4
  5. Rong Tao 5
  6. Huilai Zhang 6
  7. Laura Fogliatto 7
  8. Clara Maluquer Artigal 8
  9. MUHİT ÖZCAN ANKARA ÜNİVERSİTESİ 9
  10. Eduardo Yanez 10
  11. Won Seog Kim 11
  12. Dmitry Kirtbaya 12
  13. Iryna Kriachok 13
  14. Felipe Maciel 14
  15. Hongwei Xue 15
  16. Krimo Bouabdallah 16
  17. Charles Phelps 17
  18. Shalini Chaturvedi 18
  19. Anke Weispfenning 19
  20. Peter N Morcos 20
  21. Fatuma Odongo 21
  22. Viktoriya Buvaylo 22
  23. Barrett H Childs 23
  24. Martin Dreyling 24
  25. Matthew Matasar 25
  26. Paola Ghione 26